BioRestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 74,400 shares, a growth of 68.3% from the October 31st total of 44,200 shares. Based on an average daily volume of 25,900 shares, the days-to-cover ratio is currently 2.9 days. Approximately 1.5% of the shares of the company are sold short.

BioRestorative Therapies Stock Performance

Shares of NASDAQ BRTX traded down $0.02 during trading hours on Thursday, hitting $1.48. 14,426 shares of the stock were exchanged, compared to its average volume of 739,611. The company’s fifty day simple moving average is $1.61 and its two-hundred day simple moving average is $1.60. The company has a market cap of $10.24 million, a PE ratio of -0.97 and a beta of 63.40. BioRestorative Therapies has a 1-year low of $1.03 and a 1-year high of $3.67.

BioRestorative Therapies (NASDAQ:BRTX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.22. BioRestorative Therapies had a negative return on equity of 98.49% and a negative net margin of 2,697.08%. The firm had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.30 million. As a group, sell-side analysts expect that BioRestorative Therapies will post -1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Roth Mkm boosted their price target on BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.